 |
|
| CANCER IMMUNOTHERAPY, 90
| |
| | |
|
|
To order this title, and for more information, click here
By
James Allison, Howard Hughes Medical Institute Memorial Sloan-Kettering Cancer Center, New York, U.S.A.
Glen Dranoff, Dana-Farber Cancer Institute, Boston, MA, U.S.A.
Included in series
Advances in Immunology,
Description
For some time immunotherapy has been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy
remains solid, the approach needs considerable refinement. Whilst some programmes are looking to increase the understanding of molecular
and cellular mechanisms underlying the stimulation of antitumor immunity, others are trying to find the most appropriate clinical setting
that will reveal the role of the immune system in combating cancer. Among the most important discoveries have been tumor-specific antigens.
This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading
cancer immunotherapists from two eminent institutions that focus on cancer research.
Audience
Immunologists, research oncologists, pathologists, and cell biologists
Contents
Engineered cellular vaccines
Blockade of T cell checkpoints.
Serex in the identification of target antigens
New approaches to tumor immunotherapy
Melanoma antigens
Antibodies and chimeric molecules
Tumor Immunosurveillance
Dendritic Cells
Strategies for Tumor Vaccination
DNA vaccines
| Bibliographic details |
Hardbound, 400 pages, publication date: APR-2006
ISBN-13: 978-0-12-022489-0
ISBN-10: 0-12-022489-5
Imprint: ACADEMIC PRESS
|
| Price and Ordering |
Price:
GBP 102.99
USD 170
EUR 121.95
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
092/942
Last update: 3 Oct 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company